
Aridis Pharmaceuticals ARDS
Quarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Gross Profit 2011-2026 | ARDS
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1 K | - | - | 860 K | 342 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 860 K | 1 K | 401 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
BridgeBio Pharma
BBIO
|
38.1 M | $ 64.28 | -3.31 % | $ 12.3 B | ||
|
BioCardia
BCDA
|
141 K | $ 1.37 | 5.81 % | $ 29 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
BioLineRx Ltd.
BLRX
|
19.7 M | $ 2.82 | -0.35 % | $ 908 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 59.8 | -3.13 % | $ 11.5 B | ||
|
Bristol-Myers Squibb Company
BMY
|
18.1 B | $ 62.08 | -0.46 % | $ 126 B | ||
|
Benitec Biopharma
BNTC
|
282 K | $ 10.93 | 0.23 % | $ 450 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
BioXcel Therapeutics
BTAI
|
24.3 | $ 1.63 | -2.4 % | $ 4.13 M | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Cabaletta Bio
CABA
|
0.006 | $ 3.34 | 0.61 % | $ 3.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 4.88 | 2.74 % | $ 10.6 B | ||
|
Capricor Therapeutics
CAPR
|
310 | $ 27.28 | -2.32 % | $ 731 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Catalyst Biosciences
CBIO
|
109 M | $ 11.67 | -3.47 % | $ 768 M | ||
|
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | ||
|
C4 Therapeutics
CCCC
|
33.2 M | $ 3.06 | 13.3 % | $ 254 M | ||
|
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | ||
|
Codexis
CDXS
|
52.8 M | $ 0.99 | -2.04 % | $ 72.7 M |